SI3348557T1 - Imidazo(1,2A)piridini za zdravljenje ali preprečevanje hiperurikemije ali protina - Google Patents

Imidazo(1,2A)piridini za zdravljenje ali preprečevanje hiperurikemije ali protina

Info

Publication number
SI3348557T1
SI3348557T1 SI201630859T SI201630859T SI3348557T1 SI 3348557 T1 SI3348557 T1 SI 3348557T1 SI 201630859 T SI201630859 T SI 201630859T SI 201630859 T SI201630859 T SI 201630859T SI 3348557 T1 SI3348557 T1 SI 3348557T1
Authority
SI
Slovenia
Prior art keywords
gout
pyridines
imidazo
treating
preventing hyperuricemia
Prior art date
Application number
SI201630859T
Other languages
English (en)
Inventor
Dongfang Shi
Changjin Fu
Xi Cheng
Jianghua Zhu
Jie Wen
Jie Gu
Original Assignee
Jiangsu Atom Bioscience And Pharmaceutical Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Atom Bioscience And Pharmaceutical Co. filed Critical Jiangsu Atom Bioscience And Pharmaceutical Co.
Publication of SI3348557T1 publication Critical patent/SI3348557T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201630859T 2015-09-10 2016-09-08 Imidazo(1,2A)piridini za zdravljenje ali preprečevanje hiperurikemije ali protina SI3348557T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510576110 2015-09-10
EP16843670.7A EP3348557B1 (en) 2015-09-10 2016-09-08 Imidazo[1,2a]pyridines for treating or preventing hyperuricemia or gout
PCT/CN2016/098468 WO2017041732A1 (zh) 2015-09-10 2016-09-08 一类用于治疗或预防高尿酸血症或痛风的化合物

Publications (1)

Publication Number Publication Date
SI3348557T1 true SI3348557T1 (sl) 2020-09-30

Family

ID=58164535

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201630859T SI3348557T1 (sl) 2015-09-10 2016-09-08 Imidazo(1,2A)piridini za zdravljenje ali preprečevanje hiperurikemije ali protina

Country Status (26)

Country Link
US (1) US10399971B2 (sl)
EP (1) EP3348557B1 (sl)
JP (1) JP6635527B2 (sl)
KR (1) KR102109061B1 (sl)
CN (1) CN106432229B (sl)
AU (1) AU2016320073B2 (sl)
BR (1) BR112018004863B1 (sl)
CA (1) CA2998034C (sl)
CY (1) CY1123137T1 (sl)
DK (1) DK3348557T3 (sl)
EA (1) EA037280B1 (sl)
ES (1) ES2803223T3 (sl)
HR (1) HRP20201094T1 (sl)
HU (1) HUE051448T2 (sl)
IL (1) IL257960A (sl)
LT (1) LT3348557T (sl)
MX (1) MX2018003006A (sl)
MY (1) MY195675A (sl)
NZ (1) NZ741318A (sl)
PL (1) PL3348557T3 (sl)
PT (1) PT3348557T (sl)
RS (1) RS60697B1 (sl)
SG (1) SG11201802010QA (sl)
SI (1) SI3348557T1 (sl)
TW (1) TWI681772B (sl)
WO (1) WO2017041732A1 (sl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108084186B (zh) * 2016-11-16 2021-06-25 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
WO2018090921A1 (zh) * 2016-11-16 2018-05-24 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
CN108727267B (zh) * 2017-05-26 2022-05-13 江苏新元素医药科技有限公司 一类urat1抑制剂及其应用
WO2018214961A1 (zh) * 2017-05-26 2018-11-29 江苏新元素医药科技有限公司 促尿酸排泄的urat1抑制剂
CN117586272A (zh) * 2018-01-19 2024-02-23 苏州信诺维医药科技股份有限公司 杂环化合物、制备方法及其在医药上的应用
CN111410654B (zh) * 2019-01-19 2022-05-17 江苏新元素医药科技有限公司 3-溴-5-(2-乙基咪唑并[1,2-a]吡啶-3-羰基)-2-羟基苯甲腈的合成
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
WO2022169974A1 (en) 2021-02-05 2022-08-11 Nexys Therapeutics, Inc. Inhibitors of urat1 and pharmaceutical uses thereof
WO2023208108A1 (zh) * 2022-04-27 2023-11-02 江苏新元素医药科技有限公司 可用于降尿酸的化合物
WO2023221078A1 (en) * 2022-05-20 2023-11-23 Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. Solid forms of a compound for treating or preventing hyperuricemia or gout

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ193926A (en) * 1979-07-06 1984-05-31 Labaz Sanofi Nv 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines
FR2647451B1 (fr) * 1989-05-26 1994-08-05 Sanofi Sa Derives d'imidazo(1,2-a)pyridine, procede de preparation, compositions pharmaceutiques les contenant
JP5325065B2 (ja) * 2009-09-30 2013-10-23 株式会社富士薬品 新規フェノール誘導体
WO2012048058A2 (en) * 2010-10-06 2012-04-12 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
KR102226489B1 (ko) * 2012-07-27 2021-03-11 사토 파머슈티컬 가부시키가이샤 디플루오로메틸렌 화합물

Also Published As

Publication number Publication date
ES2803223T3 (es) 2021-01-25
US10399971B2 (en) 2019-09-03
CN106432229A (zh) 2017-02-22
PT3348557T (pt) 2020-08-03
EA037280B1 (ru) 2021-03-03
TWI681772B (zh) 2020-01-11
EP3348557A4 (en) 2019-03-06
BR112018004863A2 (sl) 2018-10-02
MY195675A (en) 2023-02-03
EA201890694A1 (ru) 2018-10-31
PL3348557T3 (pl) 2020-11-16
AU2016320073A1 (en) 2018-04-26
RS60697B1 (sr) 2020-09-30
AU2016320073B2 (en) 2019-05-09
MX2018003006A (es) 2018-08-09
HUE051448T2 (hu) 2021-03-01
TW201808284A (zh) 2018-03-16
KR102109061B1 (ko) 2020-05-11
KR20180044426A (ko) 2018-05-02
SG11201802010QA (en) 2018-04-27
EP3348557B1 (en) 2020-04-29
CY1123137T1 (el) 2021-10-29
DK3348557T3 (da) 2020-07-20
BR112018004863B1 (pt) 2023-04-18
IL257960A (en) 2018-05-31
EP3348557A1 (en) 2018-07-18
JP2018526417A (ja) 2018-09-13
CN106432229B (zh) 2018-01-12
LT3348557T (lt) 2020-08-10
CA2998034A1 (en) 2017-03-16
US20180282321A1 (en) 2018-10-04
NZ741318A (en) 2019-03-29
HRP20201094T1 (hr) 2020-10-30
CA2998034C (en) 2021-05-04
WO2017041732A1 (zh) 2017-03-16
JP6635527B2 (ja) 2020-01-29

Similar Documents

Publication Publication Date Title
SI3348557T1 (sl) Imidazo(1,2A)piridini za zdravljenje ali preprečevanje hiperurikemije ali protina
HK1254358A1 (zh) 用於治療突觸核蛋白病的藥劑、用途和方法
PL3977996T3 (pl) Leczenie zespołu tourette’a
HK1244217A1 (zh) 用於治療蛋白質病的方法
PL3484862T3 (pl) Związki, kompozycje i sposoby leczenia lub zapobiegania objawowi związanemu z dną moczanową lub hiperurykemią
EP3542829A4 (en) GARMENT PROCESSING APPARATUS
GB2567616B (en) Treatment method
EP2975020A4 (en) PROCESS FOR CLEANING 1,5-DIAMINOPENTANE
ZA201907975B (en) Agent for preventing or treating tauopathy
SG10202110763WA (en) Stenosis treatment
GB2571601B (en) Treatment method
IL283665A (en) Methods for treating or preventing rheumatism or hyperuricemia
SG10202110136XA (en) Treatment for gingivitis
EP2982378A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF SEPSIS OR SEPTIC SHOCK WITH ADK PROTEIN AS AN ACTIVE SUBSTANCE
SG11202001806TA (en) Treatment method
SG10201700825QA (en) Substrate Treating Apparatus
IL270867A (en) Treatment method
HK1254232A1 (zh) 用於治療胃潰瘍的方法和組合物
IL254336A0 (en) A new treatment method
SG11201801456TA (en) Substrate treatment apparatus
EP3305293A4 (en) METHOD OF TREATING OR PREVENTING DIABETIC NEPHROPATHY
HK1254355A1 (zh) Bace1抑制劑2-氨基-7a-苯基-3,4,4a,5,7,7a-六氫呋喃並[3,4-b]吡啶